RT Journal Article
SR Electronic
T1 Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.03.21261496
DO 10.1101/2021.08.03.21261496
A1 Israel, Ariel
A1 Merzon, Eugene
A1 Schäffer, Alejandro A.
A1 Shenhar, Yotam
A1 Green, Ilan
A1 Golan-Cohen, Avivit
A1 Ruppin, Eytan
A1 Magen, Eli
A1 Vinker, Shlomo
YR 2021
UL http://medrxiv.org/content/early/2021/08/05/2021.08.03.21261496.abstract
AB Importance Israel was among the first countries to launch a large-scale COVID-19 vaccination campaign, and quickly vaccinated its population, achieving early control over the spread of the virus. However, the number of COVID-19 cases is now rapidly increasing, which may indicate that vaccine protection decreases over time.Objective To determine whether time elapsed since the second BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) injection is significantly associated with the risk of post-vaccination COVID-19 infection.Design This is a retrospective cohort study performed in a large state-mandated health care organization in Israel.Participants All fully vaccinated adults who have received a RT-PCR test between May 15, 2021 and July 26, 2021, at least two weeks after their second vaccine injection were included. Patients with a history of past COVID-19 infection were excluded.Main Outcome and Measure Positive result for the RT-PCR test.Results The cohort included 33,993 fully vaccinated adults, 49% women, with a mean age of 47 years (SD, 17 years), who received an RT-PCR test for SARS-CoV-2 during the study period. The median time between the second dose of the vaccine and the RT-PCR test was 146 days, interquartile range [121-167] days. 608 (1.8%) patients had positive test results. There was a significantly higher rate of positive results among patients who received their second vaccine dose at least 146 days before the RT-PCR test compared to patients who have received their vaccine less than 146 days before: odds ratio for infection was 3.00 for patients aged over 60 (95% CI 1.86-5.11); 2.29 for patients aged between 40 and 59 (95% CI 1.67-3.17); and 1.74 for patients aged between 18 and 39 (95% CI 1.27-2.37); P<0.001 in each age group.Conclusions and Relevance In this large population study of patients tested for SARS-CoV-2 by RT-PCR following two doses of mRNA BNT162b2 vaccine, we observe a significant increase of the risk of infection in individuals who received their last vaccine dose since at least 146 days ago, particularly among patients older than 60.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Shamir Medical Center Institutional Review Board (129-2-LEU).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData were obtained from patients' electronic health records, and IRB approval restrains its use to researchers inside Leumit Health Services.